Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00757237 · ClinicalTrials.gov registry record · Phase 3
Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 274
- Enrollment target
NCT00757237 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 274 participants.
The verdict
NCT00757237, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 274 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the comparative safety and effectiveness of aztreonam for inhalation solution versus tobramycin inhalation solution in adult and pediatric patients with cystic fibrosis (CF) and pulmonary Pseudomonas aeruginosa (PA) infection.
Interventions
- DRUG Aztreonam for Inhalation Solution (AZLI)
- DRUG Tobramycin Inhalation Solution (TIS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2008-08 |
| Est. Completion | 2010-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00757237
The ClinicalTrials.gov registry entry for NCT00757237 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 274 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aztreonam for Inhalation Solution (AZLI) is the first listed.
NCT00757237 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00757237 about?
NCT00757237 is a clinical study titled "Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa". The purpose of this study was to assess the comparative safety and effectiveness of aztreonam for inhalation solution versus tobramycin inhalation solution in adult and pediatric patients with cystic fibrosis (CF) and pulmonary Pseudomonas aeruginosa (PA) infection.
What is the current status of trial NCT00757237?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 274 participants. The study started on 2008-08. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00757237?
The interventions under investigation include: Aztreonam for Inhalation Solution (AZLI) (DRUG), Tobramycin Inhalation Solution (TIS) (DRUG).
Who is sponsoring clinical trial NCT00757237?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.